Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Dosing complete, Pharmaxis progresses with skin scarring trials led by Professor Fiona Wood

  • In News
  • July 29, 2021
  • Samantha Freidin
Dosing complete, Pharmaxis progresses with skin scarring trials led by Professor Fiona Wood

Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before. 

More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events such as accidents, burns from fire or major surgery, scars can have debilitating physical and mental consequences.

“Scarring can have a devastating and life‐long impact on people who have suffered traumatic injuries,” said CEO of Pharmaxis, Gary Phillips. 

Specialists in fibrosis and scarring as a disease mechanism, Pharmaxis is a clinical-stage pharmaceutical company with some interesting drugs in their pipeline. One of their drugs which has just completed Phase 1a dosing in healthy volunteers is PXS-6302, a topical cream to reduce scarring using Pharmaxis’ proprietary biotechnology to inhibit the enzymes responsible for scar tissue formation. 

With limited pharmacological approaches to skin scarring available, the drug attracted the attention of Professor Fiona Wood AM. Having developed ‘spray-on skin’, commercialised by the now American-based Avita Medical (ASX: AVH), Professor Wood is one of Australia’s most innovative and respected surgeons and researchers in the field of skin scarring. 

Professor Wood is leading the world first clinical trials for Pharmaxis with PXS-6302, previously commenting, “It’s exciting  for  the  research  team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

Pharmaxis is gaining momentum with its unique approach of using anti-fibrotic molecules to develop innovative treatments, an approach that has piqued the interest of Karst Peak, a fund manager with investment interests in healthcare, biotech and pharmaceuticals.

Karst Peak was along for the ride with Avita Medical and experienced the success of spray-on skin. In April 2021 the fund manager snagged an 8.90% stake in Pharmaxis. and has since increased that to 11.27%. 

“Pharmacological approaches to skin scarring are few and far between so this program is attracting attention from clinicians, industry and market commentators alike,” added Gary Phillips. 

Set to report the results from the Phase 1a dosing study in the coming weeks, Pharmaxis can then progress to clinical trials to determine if their topical cream can prevent scar formation – an enviable position for small cap drug developers with a healthy balance sheet to fund ongoing trials. At 30 June the company had $18.7m cash in the bank and an ongoing revenue stream from its approved respiratory products.  

For the 12 months ended 30 June 2021, Pharmaxis reported a $2.9m net loss (unaudited) which represented a transformative turnaround on the $13.9m loss from the previous year as the Company approaches profitability to fuel their revolutionary drug trials. 

Pharmaxis welcomes investors to register for updates on their latest developments and industry research by joining their mailing list here.

 

*Owners of this website are PXS shareholders

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx psx
  • avita medical
  • burn scarring
  • fiona woods
  • medtech
  • pharmaxis
  • pxs
  • scar healing
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.